

IFW 1614



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: LARSSON=4

In re Application of:)	Conf. No.: 9326
)	
Anders LARSSON et al.)	Art Unit: 1614
)	
Appln. No.: 10/542,784)	Examiner: Not Yet Known
)	
Filing Date: January 26, 2006)	Washington D.C.
)	
For: USE OF AVIAN ANTIBODIES)	July 18, 2006

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window
Randolph Building, Mail Stop Amendment
401 Dulany Street
Alexandria, VA 22314

Sir:

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed before the mailing date of a first office action on the merits or before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 CFR §1.114.

2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form BN/SB/08A/B) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. Other than U.S. patent(s) and/or published U.S. application(s), which 37 CFR §1.98(a)(2)(ii) does not require to be filed

unless specifically required by the Office, a copy of each document listed is attached


3. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

4. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in 37 CFR §1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK
Attorneys for Applicant(s)


By:



Sheridan Neimark
Registration No. 20,520

SN:ma
624 Ninth Street, N.W., Suite 300
Washington, D.C. 20001-5303
Telephone: (202)628-5197
Facsimile: (202)737-3528

G:\BN\B\Bran\LARSSON4\Pto\2006-07-18 IDS Form.doc



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/542,784
Filing Date	January 26, 2006
First Named Inventor	Anders LARSSON
Group Art Unit	1614
Examiner Name	Not Yet Known
Attorney Docket Number	LARSSON=4

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Number Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

NON PATENT LITERATURE DOCUMENTS / OTHER INFORMATION

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AA	David CARLANDER et al., "Peroral Immunotherapy with Yolk Antibodies for the Prevention and Treatment of Enteric Infections", <u>Immunologic Research</u> , Vol. 21, No. 1, pp/ 1-6, 2000.	
	AB	Ronald R. MARQUARDT et al., "Passive protective effect of egg-yolk antibodies against enterotoxigenic <i>Escherichia coli</i> K88+ infection in neonatal and early-weaned piglets", <u>FEMS Immunology and Medical Microbiology</u> , Vol. 23, pp. 283-288, 1999.	
	AC	Yoshinori MINE et al., "Chicken Egg Yolk Antibodies as Therapeutics in Enteric Infectious Disease: A Review", <u>Journal of Medicinal Food</u> , Vol. 5, No. 3, pp. 159-169, 2002.	
	AD	M. A. FOLAN, "Agent for prophylaxis and therapy of chronic <i>Candida albicans</i> infections comprises immunoglobulin or fraction obtd. from body fluid of hyper-immunised animal", (C) WPI/DERWENT, 1993.	
	AE	KEMINSKI et al. "EFFICACY OF ORAL ANTI-CANDIDA EGG YOLK ANTIBODY, A FOOD NOT A DRUG", (Abstract 55), <u>Journal of the American College of Nutrition</u> , Vol.. 19, No. 5, 2000. (Session C: Gastroenterology / Preventive Nutrition).	

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.